osimertinib,everolimus
actiza,astrazeneca
['everest trial', 'lcsm,(-blcsm)', 'flaura', 'everest']
zorifertinib, a novel egfr 3rd gen tki with higher bbb penetration was tested on the everest trial for patients with brain mets. another option, yes. but it is so hard to beat the flaura trial results. does not seem better than osi. #asco23 #lcsm 
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology.  Views are my own. Member of @latenightonc - the best podcast in oncology!